Full Press Release Details
Inc. announces preliminary FIRST quarter 2025 results and RAISES H1 2025 NET SALES GUIDANCE
Unaudited Net Revenue of $39.0 million
Q1 Adjusted EBITDA above $22.5 million
Cash and Cash Equivalents of Approximately $77.5 million
NJ - April 8, 2025 - CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing
therapeutic products for life-threatening diseases and conditions, today announces its preliminary unaudited first quarter results and
provides an update on its business. These include the following key updates:
The preliminary financial information presented in
this press release is based on CorMedix's current expectations and may be adjusted as a result of, among other things, the completion
of the quarterly review procedures of CorMedix's first quarter 2025 financial statements.
is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening
conditions and diseases. The Company is focused on commercializing its lead product DefenCath (taurolidine and heparin)
which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in
outpatient settings in July 2024. CorMedix is commencing clinical studies in Total Parenteral Nutrition and Pediatric patient populations
in 2025 and also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com.
Forward-Looking Statements
This press release contains "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to risks and uncertainties, including
expectations regarding CorMedix's first quarter 2025 unaudited net revenue, adjusted EBITDA, cash and short-term investments as
of March 31, 2025 and increased net sales guidance for the first half of fiscal year 2025, and expectations regarding patient utilization
and enrollment. Forward-looking statements are often identified by the use of words such as, but not limited to, "anticipate,"
"believe," "can," "continue," "could," "estimate," "expect," "intend,"
"may," "will," "plan," "project," "seek," "should," "target,"
"will," "would," and similar expressions or variations intended to identify forward-looking statements. All statements,
other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or CorMedix's prospects
should be considered forward-looking statements. Readers are cautioned that actual results may differ materially from projections or estimates
due to a variety of important factors, and readers are directed to the Risk Factors identified in CorMedix's filings with the SEC,
including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, copies of which are available free of charge at the SEC's
website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking
statements, and such forward-looking statements speak only as of the date of this press release. Investors should not place undue reliance
on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required